These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9373324)

  • 1. Epitope mapping, V-region DNA sequence, and neutralizing Fab fragments of two monoclonal antibodies against the HIV-1 V3 loop.
    Duarte CA; Pérez L; Vázquez J; Dueñas M; Vilarrubia OL; Navea L; Valdés R; Reyes O; Montero M; Ayala M; Gavilondo J
    Immunotechnology; 1996 Feb; 2(1):11-20. PubMed ID: 9373324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
    Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
    J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.
    He Y; Honnen WJ; Krachmarov CP; Burkhart M; Kayman SC; Corvalan J; Pinter A
    J Immunol; 2002 Jul; 169(1):595-605. PubMed ID: 12077293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
    J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop.
    Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
    Pantophlet R; Aguilar-Sino RO; Wrin T; Cavacini LA; Burton DR
    Virology; 2007 Aug; 364(2):441-53. PubMed ID: 17418361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
    J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.
    Pantophlet R; Wrin T; Cavacini LA; Robinson JE; Burton DR
    Virology; 2008 Nov; 381(2):251-60. PubMed ID: 18822440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
    Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
    J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
    Laisney IL; Benjamin H; Gefter M; Strosberg AD
    Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of masking of neutralization epitopes in HIV-1.
    Agarwal A; Hioe CE; Swetnam J; Zolla-Pazner S; Cardozo T
    Vaccine; 2011 Sep; 29(39):6736-41. PubMed ID: 21216319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
    White-Scharf ME; Potts BJ; Smith LM; Sokolowski KA; Rusche JR; Silver S
    Virology; 1993 Jan; 192(1):197-206. PubMed ID: 7685962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.